Supplementary Table 1. Summary of Outcomes in Real-World Studies of Anti-VEGF Treatment (Not Including Treat-and-Extend Regimens) in Patients With nAMD*

Study	Study design	Patient population	Anti-VEGF therapy	Dosing regimen	Patients, N	Eyes, n	Outcomes during the previous 12 months
PrONTO[1]	Open-label prospective	nAMD	Ranibizumab	PRN, following loading doses	40	–	At 12 months: Mean injections: 5.6 Mean visual acuity change: +9.3 letters (p<0.001)
CATT[2]	Single-blind, randomised, prospective	nAMD	Ranibizumab	Every 28 days	284	–	At 12 months: Mean injections: 11.7 Mean visual acuity change: +8.5 letters
				PRN, following first mandatory injection	285	–	At 12 months: Mean injections: 6.9 Mean visual acuity change: +6.8 letters
			Bevacizumab	Every 28 days	265		At 12 months: Mean injections: 11.9 Mean visual acuity change: +8.0 letters
				PRN, following first mandatory injection	271		At 12 months: Mean injections: 7.7 Mean visual acuity change: +5.9 letters
SECURE[3]	Phase 4, open-label extension study	nAMD	Ranibizumab	PRN	234	–	At 24 months: Mean injections: 6.1 Mean visual acuity change: -4.3 letters
HORIZON[4]	Open-label extension study	nAMD	Ranibizumab	PRN (initially treated with ranibizumab)	600	–	At 24 months: Mean injections: 4.4 Mean visual acuity change: -7.0 letters
				PRN (crossover to ranibizumab)	190	–	At 24 months: Mean injections: 4.8

							Mean visual acuity change: -2.2 letters
TWIN[5]	Retrospective observational study	nAMD	Ranibizumab	PRN, following loading doses	881	–	At 12 months: Mean injections: 5.6 Mean visual acuity change: +4.3 letters
AURA[6]	Retrospective observational study	nAMD	Ranibizumab	PRN, following loading doses	2227	–	At 24 months: Mean injections: 7.2 Mean visual acuity change: +0.6 letters
LUMINOUS[7, 8]	Prospective observational study	nAMD	Ranibizumab	PRN, following loading doses	2701	–	At 12 months: Mean injections: 5.3 Mean visual acuity change: +3.6 letters
					372		Mean visual acuity change with <3 injections: +2.1 letters
					1499		Mean visual acuity change with 3–6 injections: +3.6 letters
					830		Mean visual acuity change with >6 injections: +4.3 letters
IRIS[9]	Retrospective, non-randomised, comparative registry study	nAMD	Ranibizumab	PRN	2749	–	At 12 months: Mean injections: 6.4 Mean visual acuity change: -0.05 logMAR
			Aflibercept	PRN	4387	–	At 12 months: Mean injections: 6.2 Mean visual acuity change: -0.04 logMAR
			Bevacizumab	PRN	6723	–	At 12 months: Mean injections: 5.9 Mean visual acuity change: -0.05 logMAR

Talks et al.[10]	Retrospective review of medical records	nAMD	Aflibercept	Fixed bimonthly, following loading doses	1682	1840	At 12 months: Mean injections: 7.0 Mean visual acuity change: +5.1 letters
PERSEUS[11]	Prospective, non-interventional, non-controlled, multicentre, observational cohort study	nAMD	Aflibercept	Fixed bimonthly (treatment-naïve), following loading doses	447	–	At 12 months: Mean injections: 7.4 Mean visual acuity change: +8.0 letters
				PRN (treatment-naïve)			At 12 months: Mean injections: 5.1 Mean visual acuity change: +4.0 letters
				Fixed bimonthly (previously treated), following loading doses	355	–	At 12 months: Mean injections: 7.5 Mean visual acuity change: +3.1 letters
				PRN (previously treated)			At 12 months: Mean injections: 5.3 Mean visual acuity change: -1.1 letters
Lee et al.[12]	Retrospective review of medical records	nAMD	Aflibercept	Fixed bimonthly, following loading doses	–	942	At 12 months: Mean injections: 7.0 Mean visual acuity change: +6.1 letters ($p<0.001$)
			Ranibizumab	PRN	–	942	At 12 months: Mean injections: 5.8 Mean visual acuity change: +1.6 letters
Airody et al.[13]	Single-centre cohort	nAMD	Ranibizumab	PRN, following loading doses	68	–	At 60 months: Median injections: 6, 4, 4, 4, 7 in Year 1–5, respectively Mean visual acuity change: +5.7 letters

Almuhtaseb et al.[14]	Retrospective review of medical records	nAMD	Aflibercept	Fixed bimonthly, following loading doses	223	255	At 12 months: Mean injections: 7.0 Mean visual acuity change: -0.16 logMAR
Almuhtaseb et al.[15]	Retrospective review of medical records	nAMD	Aflibercept	Fixed bimonthly in Year 1, PRN in Year 2, following loading doses	1083	1180	At 12 months: Mean visual acuity change: +5.0 letters From 12 to 24 months: Mean injections: 3.7 Mean visual acuity change: +2.8 letters
Arias et al.[16]	Prospective, non-comparative, consecutive case series study	nAMD	Ranibizumab	PRN, following loading doses	88	90	At 12 months: Mean injections: 4.4 Mean visual acuity change: +7 letters
Barthelmes et al.[17]	Registry study	Exudative nAMD switching treatment after ≥12 months (mean 39.8 months) treatment with ranibizumab	Aflibercept	PRN, following loading doses	–	384	At 12 months after switch: Mean injections: 3.2 Mean visual acuity change: -0.1 letters
Berg et al.[18]	Retrospective review of medical records	nAMD	Bevacizumab	PRN, following monthly dosing until there were	40		At Year 8: Mean injections: 5.4 Mean visual acuity change: -2.1 letters

				no signs of active nAMD			
Biarnés et al.[19]	Retrospective, consecutive case series	nAMD	Ranibizumab	PRN	71	67	At 12 months: Mean injections: 3.5 Mean visual acuity change: +1.3 letters
Böhni et al.[20]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	15	16	At 12 months: Mean injections: 8.3 Mean visual acuity change: +15.0 letters
			Aflibercept	PRN, following loading doses	9	11	At 12 months: Mean injections: 8.5 Mean visual acuity change: +5.6 letters
Braimah et al.[21]	Retrospective review of medical records	Patients with nAMD switched from bevacizumab and ranibizumab	Aflibercept	PRN	14	16	At 12 months: Mean injections: 5.9 Mean visual acuity change: No change
UNCOVER[22]	Retrospective cohort study	nAMD	Ranibizumab	–	3241	3725	At mean 22.3 months: Mean injections: 4.2 per year Mean visual acuity change: -0.7 letters
Elwes et al.[23]	Retrospective review of medical records	nAMD	Aflibercept, switching from ranibizumab	PRN, following loading doses	182	207	At 85 weeks: Mean injections: 10 Mean visual acuity change: -8.9 letters

WAVE[24]	Prospective observational study	nAMD	Ranibizumab	PRN, following loading doses	2587	–	At 12 months: Mean injections: 4.3 Mean visual acuity change: +0.02 logMAR
Gabai et al.[25]	Retrospective review of patient records	nAMD	Ranibizumab	PRN, following loading doses	92	100	At 12 months: Mean injections: 4.8 Mean visual acuity change: -2.0 letters
Garweg et al.[26]	Retrospective review of medical records	nAMD	Any anti-VEGF therapy	PRN, following loading doses	104	104	At Years 3–10: Mean injections: 2.8 annually Mean visual acuity change: -7.3 to -11.9 letters
Gerding et al.[27]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	–	104	At 12 months: Mean injections: 5.8 Mean visual acuity change: +5.0 letters
Giacomelli et al.[28]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	31	–	At 12 months: Mean injections: 5.1 Mean visual acuity change: +0.14 logMAR At 24 months: Mean injections: 7.6 Mean visual acuity change: +0.25 logMAR

Giannou et al.[29]	Prospective cohort study	nAMD	Ranibizumab	Observe-and-plan	104	115	At 12 months: Mean injections: 7.8 Mean visual acuity change: +9.7 letters At 24 months: Mean injections: 13.6 Mean visual acuity change: +9.2 letters
Fight Retinal Blindness! Study[30]	Prospective observational study	nAMD	Ranibizumab	–	–	197	At 12 months: Mean injections: 8.1 Mean visual acuity change: +2.9 letters
			Aflibercept	–	–	197	At 12 months: Mean injections: 8.0 Mean visual acuity change: +5.4 letters
Heimes et al.[31]	Prospective observational study	nAMD	Ranibizumab	PRN, following loading doses	–	152	At 12 months: Mean injections: 5 Mean visual acuity change: 0 logMAR
Kang and Roh[32]	Retrospective review of medical records	nAMD	Ranibizumab	PRN (without a loading dose)	41	41	At 12 months: Mean injections: 4.1 Mean visual acuity change: -0.078 logMAR ($p<0.05$)
Lala et al.[33]	Retrospective review of medical records	Exudative AMD	Ranibizumab	PRN, following loading doses	284 208	284 208	At 12 months: Mean injections: 7.1 Mean visual acuity change: +7.5 letters At 24 months:

					152	152	Mean injections: 5.0 Mean visual acuity change: +9.1 letters At 36 months: Mean injections: 5.2 Mean visual acuity change: +8.3 letters
Liew et al.[34]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	–	5811	At 12 months: Median injections: 6.0 Mean visual acuity change: +2.5 letters
Lotery et al.[35]	Retrospective, comparative, non-randomised cohort study	nAMD	Ranibizumab	Regimen not defined	–	3350	At 12 months: Median injections: 6.7 Mean visual acuity change: -0.30 letters
			Aflibercept	Regimen not defined	–	4300	At 12 months: Median injections: 7.0 Mean visual acuity change: -0.19 letters
Marques et al.[36]	Retrospective review of medical records	nAMD	Ranibizumab	PRN	77	84	At 36 months: Mean injections: 8.6 Mean visual acuity change: +0.19 letters
Muftuoglu et al.[37]	Prospective interventional study	Patients with nAMD who failed treatment with ranibizumab or bevacizumab or aflibercept every 8 weeks	Aflibercept	PRN	39	43	At 12 months: Mean injections: 8 Mean visual acuity change: +0.02 logMAR
Muniraju et al.[38]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	156	174	At 12 months: Mean injections: 4.8

							Mean visual acuity change: +3.0 letters (p<0.05) At 24 months: Mean injections: 2.9 Mean visual acuity change: +2.2 letters At 36 months: Mean injections: 2.4 Mean visual acuity change: +0.9 letters
Ozkaya et al.[39]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	37	44	At 12 months: Mean injections: 3.9 Mean visual acuity change: -0.02 logMAR At 24 months: Mean injections: 2.6 Mean visual acuity change: +0.09 logMAR At 36 months: Mean injections: 2.1 Mean visual acuity change: +0.23 logMAR At 48 months: Mean injections: 2.0 Mean visual acuity change: +0.27 logMAR At 60 months: Mean injections: 2.3 Mean visual acuity change: +0.29 logMAR

Parvin et al.[40]	Prospective non-comparative case series	nAMD	Aflibercept	Observe-and-plan, following loading doses	102	112	At 12 months: Mean injections: 8.7 Mean visual acuity change: +8.0 letters (p<0.001) At 24 months: Mean injections: 6.3 Mean visual acuity change: +6.2 letters (p<0.001)
Peden et al.[41]	Retrospective review of medical records	Exudative AMD	Any anti-VEGF therapy	Continuous fixed dosing every 4–8 weeks (mean 10.5 injections/year)	109	–	At 60 months: Mean visual acuity change: +14.0 letters (p<0.001)
					75	–	At 72 months: Mean visual acuity change: +12.2 letters (p<0.001)
					44	–	At 84 months: Mean visual acuity change: +12.1 letters (p<0.001)
Rasmussen et al.[42]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	559	616	At 12 months: Mean injections: 6.9 Mean visual acuity change: +0.08 Snellen (p<0.001)
			Aflibercept		468	527	At 12 months: Mean injections: 5.9 Mean visual acuity change: +0.08 Snellen (p<0.001)

Rasmussen et al.[43]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	192	192	At 12 months: Mean injections: 5.2 Mean visual acuity change: +0.05 Snellen (p<0.001) At 24 months: Mean injections: 5.0 At 36 months: Mean injections: 5.5 At 48 months: Mean injections: 6.4 Mean visual acuity change: +0.02 Snellen
Ricci et al.[44]	Retrospective review of medical records	nAMD switched from ranibizumab	Aflibercept	PRN, following loading doses	–	36	At 12 months: Mean injections: 3.5 Mean visual acuity change: -3 letters
				Fixed dosing bimonthly, following loading doses	–	36	At 12 months: Mean injections: 7.0 Mean visual acuity change: +3 letters (p<0.01; p=0.01 versus PRN)
Saleh et al.[45]	Prospective cohort study	Exudative AMD	Aflibercept	PRN, following loading doses	60	66	At 24 months: Mean injections: 5/year Mean visual acuity change: +1.0 letters
LUEUR[5]	Prospective cohort study	nAMD (total study population)	Ranibizumab	PRN, following loading doses	517	592	At 12 months: Mean injections: 2.9 Mean visual acuity change: +0.1 letters At 24 months:

							Mean injections: 2.2 Mean visual acuity change: -2.0 letters
		nAMD (treatment-naïve population)		PRN, following loading doses	–	90	At 12 months: Mean injections: 3.4 Mean visual acuity change: +2.1 letters At 24 months: Mean injections: 1.6 Mean visual acuity change: -0.2 letters
Westborg et al.[46]	Retrospective registry study	nAMD	Any anti-VEGF therapy	Regimen not defined	–	–	At 84 months: Mean injections: 3/year Mean visual acuity change: -1.0 letters
PACORES[47, 48]	Retrospective review of medical records	nAMD	Bevacizumab	PRN	63	63	At 12 months: Mean injections: 3.5 Mean visual acuity change: -0.2 logMAR (p<0.001)
					247	292	At 60 months: Mean injections: 10.9 over 5 years Mean visual acuity change: +0.2 logMAR (p<0.001)
Axer-Siegel et al.[49]	Retrospective review of medical records	Exudative AMD	Bevacizumab	PRN, following loading doses	130	150	At 20.2 months: Mean injections: 11.3 Mean visual acuity change: No change
Bashshur et al.[50]	Prospective, open-label, non-randomised clinical study	CNV resulting from nAMD	Bevacizumab	PRN, following loading doses [51]	51	51	At 24 months: Mean injections in Year 2: 1.5 Mean visual acuity change: +8.6 letters (p=0.001)
Bellerive et al.[52]		nAMD	Bevacizumab	PRN, following loading doses	–	142	At 12 months: Mean injections: 4.8

	Retrospective review of medical records						Mean visual acuity change: -0.03 logMAR
			Ranibizumab	PRN, following loading doses	–	50	At 12 months: Mean injections: 4.9 Mean visual acuity change: -0.06 logMAR
Beykin et al.[53]	Retrospective review of medical records	CNV resulting from nAMD	Bevacizumab (with second line ranibizumab therapy for patients experiencing treatment failure)	PRN, following loading doses	128	142	Mean injections per year: 5.4 At 12 months: Mean visual acuity change: +8.8 letters (p<0.05) At 24 months: Mean visual acuity change: +7.8 letters (p<0.05) At 36 months: Mean visual acuity change: -1.2 letters At ≥48 months (mean 60 months): Mean visual acuity change: -1.7 letters
Calvo et al.[54]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	51	51	Mean injections over 3 years: 6.98 At 12 months: Mean visual acuity change: -0.17 logMAR
Chang et al.[55]	Retrospective review of medical records	Exudative AMD in eyes with initial visual acuity of 20/25 or better	Ranibizumab or bevacizumab	PRN, following loading doses	18	18	At 12 months: Mean injections: 4.4 Mean visual acuity change: +0.08 logMAR (p=0.009)
LUMIERE[56]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	551	–	At 12 months: Mean injections: 5.1 Mean visual acuity change: +3.2 letters
De Bats et al.[57]	Retrospective case-control study	nAMD	Bevacizumab	PRN, following loading doses	30	–	At 12 months: Mean injections: 4.8 Mean visual acuity change: -0.23 logMAR

			Ranibizumab		28	–	At 12 months: Mean injections: 5.8 Mean visual acuity change: -0.01 logMAR
Eleftheriadou et al.[58]	Retrospective case series	nAMD (treatment-naïve)	Aflibercept	Fixed dosing in Year 1, following loading doses, then treat-and-extend	139	148	At 12 months: Mean injections: 7.2 Mean visual acuity change: +5.9 letters At 24 months: Mean injections: 12 Mean visual acuity change: +6.4 letters At 36 months: Mean injections: 15.9 Mean visual acuity change: +6.6 letters
Gupta et al.[59]	Retrospective review of medical records	nAMD and CND (treatment naïve)	Ranibizumab	PRN, following loading doses	47	47	At 12 months: Mean injections: 6.0 Mean visual acuity change: +4.4 letters
				PRN, following one injection at baseline	31	31	At 12 months: Mean injections: 4.5 Mean visual acuity change: +4.0 letters
Hjelmqvist et al.[60]	Open-label, prospective and retrospective observational study	Wet AMD	Ranibizumab	PRN, following loading doses	370	-	At 12 months: Mean injections: 7.7 Mean visual acuity change: +1.0 letter
HELIX[61]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	69	88	At 12 months: Mean injections: 5.2 Mean visual acuity change: +3.7 letters At 24 months: Mean injections in Year 2: 3.2 Mean visual acuity change: +2.4 letters

							At 36 months: Mean injections in Year 3: 3.1 Mean visual acuity change: +1.1 letters At 48 months: Mean injections in Year 4: 3.2 Mean visual acuity change: +2.6 letters At 60 months: Mean injections in Year 5: 3.1 Mean visual acuity change: -1.1 letters At 72 months: Mean injections in Year 6: 2.5 Mean visual acuity change: -1.6 letters
Krüger et al.[62]	Retrospective review of medical records	nAMD	Ranibizumab	PRN (according to Danish Guidelines), following loading doses	855	855	At 48 months (mean follow-up): Mean injections: 8.7 over 48 months Mean visual acuity change: -2.7 letters
Lalwani et al.[63]	Open-label prospective study	nAMD	Ranibizumab	PRN, following loading doses	40	-	At 24 months: Mean injections: 9.9 over 24 months Mean visual acuity change: +11.1 letters ($p<0.001$)
Mantel et al.[64]	Open-label prospective study	nAMD and CNV (treatment-naïve)	Ranibizumab	Observe-and-plan, following loading doses	104	115	At 12 months: Mean injections: 7.8 injections Mean visual acuity change: +8.7 letters
Mekjavic et al.[65]	Retrospective review of medical records	nAMD and CNV	Ranibizumab	PRN, following loading doses	147	149	At 12 months: Mean injections: 5.1 injections Mean visual acuity change: +6 letters ($p<0.0001$)

Messenger et al.[66]	Retrospective review of medical records	nAMD previously treated with bevacizumab or ranibizumab for at least 12 months	Aflibercept	PRN, following loading dose	109	109	At 12 months: Mean injections: 7.2 injections Mean visual acuity change: No change
Muether et al.[67]	Open-label prospective study	nAMD	Ranibizumab	PRN, following loading dose	89	–	At 12 months: Mean injections: 6.9 injections Mean visual acuity change: -0.66 letters
Ohnaka et al.[68]	Retrospective review of medical records	nAMD	Aflibercept	Modified treat-and-extend	36	36	At 12 months: Mean injections: 4.5 injections Mean visual acuity change: -0.08 logMAR ($p<0.01$)
HELIOS (Belgium)[69]	Prospective, observational, open-label study	Wet AMD	Ranibizumab	PRN	267	309	At 12 months: Mean injections: 5.0 Mean visual acuity change: +1.6 letters At 24 months: Mean injections: 7.6 Mean visual acuity change: -2.4 letters
HELIOS (The Netherlands)[70]					243	–	At 12 months: Mean injections: 5.5 Mean visual acuity change: +4.4 letters At 24 months: Mean injections: 7.8 Mean visual acuity change: +1.0 letters
Suzuki et al.[71]	Retrospective review of medical records	nAMD and CNV	Bevacizumab	PRN	47		At 12 months: Mean injections: 3.4

							Mean visual acuity change: +0.04 logMAR
Warwick et al.[72]	Retrospective review of medical records	nAMD (Treatment-naïve)	Aflibercept	3 monthly loading doses followed by injection every 2 months	51	58	At 12 months: Mean injections: 7.1 Mean visual acuity change: +4.7 letters (p<0.001)
		nAMD (Treatment-experienced)			88	107	At 12 months: Mean injections: 7.5 Mean visual acuity change: +3.3 letters (p<0.01)
RAINBOW[73]	Observational, retrospective and prospective	Wet AMD	Aflibercept	Fixed (bimonthly)	012		At 12 months: Mean injections: 7.2 Mean visual acuity change: +7.1 letters (p<0.001; p<0.001 versus PRN without loading dose)
				PRN (with loading dose)	266		At 12 months: Mean injections: 6.1 Mean visual acuity change: +5.6 letters (p<0.001; p=0.003 versus PRN without loading dose)
				PRN (without loading dose)	60		At 12 months: Mean injections: 5.2 Mean visual acuity change: +5.0 letters (p<0.001)
Lovestam Adrian et al.[74]	Observational, retrospective	nAMD	Aflibercept	PRN, following loading dose	2312	12 months: 2478 24 months: 831	At 12 months: Mean visual acuity change from baseline overall: +3.2 letters At 24 months:

							Mean visual acuity change from baseline overall: +3.8
Barakat et al.[75]	Observational, retrospective	nAMD	Aflibercept	Loading phase, PRN (Weeks 12 to 32), then treat-and-extend	38	48	At 12 months: Mean injections: 6 Mean visual acuity change: +6.0 letters At 24 months: Mean injections: 3.2 Mean visual acuity change: +5.2 letters
Ono et al.[76]	Interventional, case series, prospective	Exudative AMD	Aflibercept	3 monthly loading doses followed by injection every 2 months	48	48	At 12 months: Total injections: 7 Mean overall visual acuity change: LogMAR -0.13 (p=0.008; vs baseline)
Chatziralli et al.[77]	Observational, retrospective	nAMD	Aflibercept	Bimonthly dosing in Year 1, following loading dose	-	2506 (<90 years of age)	At 12 months: Mean visual acuity: +4.6 letters At 24 months: Mean visual acuity: +2.1
Brand et al.[78]	Observational, retrospective	nAMD	Ranibizumab monotherapy	3 month loading doses then PRN	50	-	At 12 months: Mean injections: 5.6 Mean visual acuity change: -0.3 letters
			Ranibizumab + stereotactic radiotherapy	Stereotactic therapy during 3-month loading dose then PRN	132	-	At 12 months: Mean injections: 4.5 Mean visual acuity change: +3.0 letters

*All visual acuity changes are relative to baseline. Mean injections are the number of injections in the preceding 12-month period. p-values are versus baseline unless otherwise stated.

AMD, age-related macular degeneration; CNV, choroidal neovascularisation; logMAR, log of the Minimum Angle of Resolution; nAMD, neovascular AMD; PRN, pro re nata; VEGF, vascular endothelial growth factor.

Supplementary Table 2. Summary of Outcomes in Real-World Studies of Anti-VEGF Treatment (Including Treat-and-Extend Regimens) in Patients With nAMD*

Study	Study design	Patient population	Anti-VEGF therapy	Dosing regimen	Patients, N	Eyes, n	Outcomes during the previous 12 months
Oubraham et al.[79]	Retrospective consecutive case series	Exudative AMD	Ranibizumab	PRN, following loading doses	52	–	At 12 months: Mean injections: 5.2 Mean visual acuity change: +2.3 letters
				Treat-and-extend, following loading doses	38	–	At 12 months: Mean injections: 7.8 Mean visual acuity change: +10.8 letters ($p<0.05$)
Hatz and Prünte[80]	Retrospective, consecutive, comparative case series of treatment-naïve patients	nAMD	Ranibizumab	PRN (mean duration: 17 months), following loading doses	134	146	Mean BCVA (±SD) increased from 0.39±0.23 to 0.55±0.22 ($p<0.001$) during the PRN loading regimen, then declined to 0.49±0.22 ($p<0.001$)
				Treat-and-extend			BCVA improved from 0.49±0.22 to 0.55±0.23 and 0.56±0.24 by 6 and 12 months, respectively ($p<0.001$)
Fight Retinal Blindness! Study[81]	Observational registry	nAMD	Predominantly ranibizumab	Treat-and-extend, following loading doses until CNV activity had resolved	1101	1198	At 24 months: Mean injections: 13.0 (7.5 in Year 1 and 5.5 in Year 2) Mean visual acuity change: +5.3 letters

Fight Retinal Blindness! Study[82]	Observational registry	nAMD	Aflibercept	Treat-and-extend, following loading doses	123	136	At 24 months: Mean injections: 13.6 (7.8 in Year 1 and 5.7 in Year 2) Mean visual acuity change: +6.0 letters
Abedi et al.[83]	Prospective cohort study	nAMD	Ranibizumab or bevacizumab	Treat-and-extend, following loading doses	120	–	At 12 months: Mean injections: 8.6 Mean visual acuity change: +9.5 letters At 24 months: Mean injections: 5.6 Mean visual acuity change: +8.0 letters
Castro-Navarro et al.[84]	Retrospective review of medical records	Exudative nAMD	Aflibercept	Treat-and-extend, following loading doses	30	30	At 12 months: Mean injections: 7.4–8.7 Mean visual acuity change: -0.23 logMAR
Castro-Navarro et al.[85]	Retrospective review of medical records	Exudative nAMD with secondary CNV and retinal angiomatous proliferation	Aflibercept	Treat-and-extend, following loading doses	–	37	At 12 months: Mean injections: 7.3–8.0 Mean visual acuity change: -0.20 logMAR
Chen et al.[86]	Retrospective review of medical records	nAMD	Ranibizumab	Treat-and-extend, following loading doses	79	–	At 12 months: Mean injections: 8.6 Mean visual acuity change: +7.9 letters
Garweg et al.[87]	Retrospective review of medical records	nAMD	Ranibizumab	PRN, following loading doses	61	68	At 12 months: Mean injections: 5.5 Mean visual acuity change: +0.66 letters At 24 months:

							Mean injections in Year 2: 1.9 Mean visual acuity change: -3.67
				Treat-and-extend, following loading doses	35	39	At 12 months: Mean injections: 6.8 Mean visual acuity change: +2.65 letters At 24 months: Mean injections in Year 2: 3.8 Mean visual acuity change: +1.43 letters
Giannakaki-Zimmerman et al.[88]	Retrospective observational study	AMD and CNV switch from PRN to treat-and-extend	Aflibercept	PRN	32	–	12 months prior to crossover: Mean injections: 6.0 Mean visual acuity change: -0.0 letters
				Treat-and-extend			At 12 months: Mean injections: 7.5 Mean visual acuity change: -0.65 letters
Gupta et al.[89]	Retrospective review of medical records	nAMD	Ranibizumab	Treat-and-extend, following loading doses	92	92	At 12 months: Mean injections: 8.4 Mean Snellen visual acuity: 20/77 (from 20/135 at baseline;p<0.001) At 24 months: Mean injections: 7.5 Mean Snellen visual acuity: 20/83 (p=0.002)
Hatz and Prünte[90]	Retrospective study consisting of two consecutive, comparative	nAMD	Ranibizumab	PRN, following loading doses	70	70	At 12 months: Mean injections: 6.0 Mean visual acuity change: +0.07 letters
				Treat-and-extend, following loading doses	70	70	At 12 months: Mean injections: 8.6 Mean visual acuity change: +0.18 letters

	case series						
Ito et al.[91]	Retrospective review of medical records	nAMD	Aflibercept	Treat-and-extend, following loading doses	–	61	At 24 months: Mean injections: 13.6 Mean visual acuity change: -0.13 logMAR
Makjevic and Benda[92]	Retrospective review of medical records	nAMD	Ranibizumab or bevacizumab	Treat-and-extend, following loading doses	101	101	At 12 months: Mean injections: 8.0 Mean visual acuity change: +6.8 letters
							At 24 months: Mean injections: 6.3 Mean visual acuity change: +5.9 letters
							At 36 months: Mean injections: 5.9 Mean visual acuity change: +4.0 letters
							At 48 months: Mean injections: 5.4 Mean visual acuity change: +0.9 letters
							At 60 months: Mean injections: 4.0 Mean visual acuity change: -1.9 letters
Jørstad et al.[93]	Prospective observational study	Exudative AMD and persistent macular fluid despite monthly treatment with ranibizumab or bevacizumab	Aflibercept	Treat-and-extend, following loading doses until no signs of active AMD	47	50	At 12 months: Mean injections: 9.2 Mean visual acuity change: -0.01 logMAR At 24 months: Mean injections: 8.0 Mean visual acuity change: +0.07 logMAR (p=0.005)

Rahimy et al.[94]	Retrospective observational case series	nAMD with initial vision better than 20/40	Ranibizumab or bevacizumab	Treat-and-extend, following monthly dosing until no signs of CNV were detectable	40	42	At 12 months: Mean injections: 7.8 Mean visual acuity change: +0.031 logMAR At 24 months: Mean injections: 6.1 Mean visual acuity change: +0.041 logMAR
Rayess et al.[95]	Retrospective, consecutive case series	nAMD	Ranibizumab or bevacizumab	Treat-and-extend, following loading doses	189	212	At 12 months: Mean injections: 7.6 Mean visual acuity change: +11.6 letters At 24 months: Mean injections: 5.7 Mean visual acuity change: +10.7 letters At 36 months: Mean injections: 5.8 Mean visual acuity change: +13.6 letters
Vardarinos et al.[96]	Retrospective review of medical records	nAMD	Ranibizumab	Treat-and-extend, following loading doses	60		At 12 months: Mean injections: 7.8 Mean visual acuity change: +8.3 letters At 24 months: Mean injections: 12.1 Mean visual acuity change: +5.2 letters
Westborg et al.[46]	Retrospective registry study	nAMD	Any anti-VEGF therapy	Regimen not defined	–	–	At 84 months: Mean injections: 3/year Mean visual acuity change: -1.0 letters

Yamamoto et al.[97]	Retrospective review of medical records	nAMD	Aflibercept	Treat-and-extend, following loading doses	67	67	At 12 months: Mean injections: 8.3 Mean visual acuity change: -0.15 logMAR (p<0.001)
Engelbert et al.[98]	Retrospective case-control study	Type 1 AMD	Bevacizumab and/or ranibizumab	Modified treat-and-extend, following loading doses	16	18	At 24 months: Mean injections: 12 Mean visual acuity change: -0.01 logMAR At 36 months: Mean injections: 20 Mean visual acuity change: -0.01 logMAR
Garweg et al.[99]	Retrospective comparative case series	Exudative AMD	Aflibercept	Treat-and-extend, following loading doses	99	106	At 12 months: Mean injections: 7.5 Mean visual acuity change: Stable At 24 months: Mean injections: 11.8 Mean visual acuity change: Stable
			Ranibizumab		43	47	At 12 months: Mean injections: 6.9 Mean visual acuity change: Stable At 24 months: Mean injections: 10.3 Mean visual acuity change: Stable
Rush et al.[100]	Retrospective review of medical records	nAMD	Bevacizumab	Treat-and-extend	–	230	At 12 months: Mean injections: 9.2 injections Mean visual acuity change: -0.09 logMAR (p<0.001)

Sakamoto et al.[101]	Prospective, interventional, open-label study	Exudative AMD	Aflibercept	Fixed (bimonthly), following loading dose Treat-and-extend (in Year 2)	47	47	At 12 months: Mean injections: 6.7 Mean visual acuity change: -0.04 logMAR ($p<0.05$) At 24 months: Mean injections: 4.8 Mean visual acuity change: -0.03 logMAR
Shienbaum et al.[102]	Retrospective review of medical records	nAMD	Bevacizumab	Treat-and-extend	73	74	At 12 months: Mean injections: 7.9 Mean Snellen visual acuity: 20/109 (20/230 at baseline; $p<0.05$)

AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; logMAR, log of the Minimum Angle of Resolution; nAMD, neovascular AMD; PRN, pro re nata; VEGF, vascular endothelial growth factor.

*All visual acuity changes are relative to baseline.

References

1. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. *Am J Ophthalmol* 2007;143:566-83 doi: 10.1016/j.ajo.2007.01.028.
2. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med* 2011;364:1897-908 doi: 10.1056/NEJMoa1102673 [published Online First: 28 April 2011].
3. Silva R, Axer-Siegel R, Eldem B, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. *Ophthalmology* 2013;120:130-9 doi: 10.1016/j.ophtha.2012.07.026 [published Online First: 25 September 2012].
4. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology* 2012;119:1175-83 doi: 10.1016/j.ophtha.2011.12.016 [published Online First: 04 February 2012].
5. Souied E, Oubraham H, Mimoun G, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clnical practice: The TWIN Study. *Retina* 2015;35:1743-9 doi: 10.1097/iae.0000000000000548 [published Online First: 23 April 2015].
6. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. *Br J Ophthalmol* 2015;99:220-6 doi: 10.1136/bjophthalmol-2014-305327 [published Online First: 07 September 2014].
7. Holz FG. Effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration: Twelve-month results from the final analysis of the real-world LUMINOUS study *EURETINA* 2017.
8. Souied E, Clemens A, Macfadden W. Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study [abstract]. *Acta Ophthalmol* 2017 doi: 10.1111/j.1755-3768.2017.01111.
9. Rao P, Lum F, Wood K, et al. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. *Ophthalmology* 2018;125:522-28 doi: 10.1016/j.ophtha.2017.10.010 [published Online First: 13 November 2017].
10. Talks JS, Lotery AJ, Ghanchi F, et al. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. *Ophthalmology* 2016;123:337-43 doi: 10.1016/j.ophtha.2015.09.039 [published Online First: 12 November 2015].
11. Framme C. Impact of treatment interval in naïve nAMD patients: 12-month results of the PERSEUS and RAINBOW studies *EURETINA* 2017.
12. Lee AY, Lee CS, Egan CA, et al. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. *Br J Ophthalmol* 2017;101:1683-88 doi: 10.1136/bjophthalmol-2016-309818 [published Online First: 06 May 2017].

13. Airody A, Venugopal D, Allgar V, et al. Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab. *Acta Ophthalmol* 2015;93:e511-2 doi: 10.1111/aos.12618 [published Online First: 10 December 2014].
14. Almuhtaseb H, Kanavati S, Rufai SR, et al. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. *Eye (Lond)* 2017;31:878-83 doi: 10.1038/eye.2017.6 [published Online First: 12 February 2017].
15. Almuhtaseb H, Johnston RL, Talks JS, et al. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group. *Eye (Lond)* 2017;31:1582-88 doi: 10.1038/eye.2017.108 [published Online First: 18 June 2017].
16. Arias L, Roman I, Masuet-Aumatell C, et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. *Retina* 2011;31:1261-7 doi: 10.1097/IAE.0b013e318207d152 [published Online First: 19 April 2011].
17. Barthelmes D, Campain A, Nguyen P, et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. *Br J Ophthalmol* 2016;100:1640-45 doi: 10.1136/bjophthalmol-2015-308090 [published Online First: 20 March 2016].
18. Berg K, Roald AB, Navaratnam J, et al. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. *Acta Ophthalmol* 2017;95:796-802 doi: 10.1111/aos.13522 [published Online First: 20 September 2017].
19. Biarnes M, Mones J, Villalbi JR, et al. As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. *Eur J Ophthalmol* 2011;21:282-9 doi: 10.5301/ejo.2010.5766 [published Online First: 05 October 2010].
20. Bohni SC, Bittner M, Howell JP, et al. Comparison of Eylea(R) with Lucentis(R) as first-line therapy in patients with treatment-naive neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis. *BMC Ophthalmol* 2015;15:109 doi: 10.1186/s12886-015-0101-4 [published Online First: 21 August 2015].
21. Braimah IZ, Agarwal K, Mansour A, et al. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration. *Br J Ophthalmol* 2018;102:91-96 doi: 10.1136/bjophthalmol-2017-310318 [published Online First: 10 June 2017].
22. Eldem B, Lai TYY, Ngah NF, et al. An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. *Graefes Arch Clin Exp Ophthalmol* 2018;256:963-73 doi: 10.1007/s00417-017-3890-8 [published Online First: 05 March 2018].
23. Elwes F, Borooah S, Aspinall P, et al. Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. *BMC Ophthalmol* 2018;18:20 doi: 10.1186/s12886-018-0688-3 [published Online First: 31 January 2018].
24. Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. *Acta Ophthalmol* 2013;91:540-6 doi: 10.1111/j.1755-3768.2012.02493.x [published Online First: 23 November 2012].

25. Gabai A, Veritti D, Lanzetta P. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical setting. *Eur J Ophthalmol* 2014;24:396-401 doi: 10.5301/ejo.5000385 [published Online First: 19 November 2013].
26. Garweg JG, Zirpel JJ, Gerhardt C, et al. The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. *Graefes Arch Clin Exp Ophthalmol* 2018;256:823-31 doi: 10.1007/s00417-018-3907-y [published Online First: 06 February 2018].
27. Gerding H, Loukopoulos V, Riese J, et al. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. *Graefes Arch Clin Exp Ophthalmol* 2011;249:653-62 doi: 10.1007/s00417-011-1636-6 [published Online First: 10 March 2011].
28. Giacomelli G, Giansanti F, Finocchio L, et al. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration. *Retina* 2014;34:860-7 doi: 10.1097/iae.0000000000000007 [published Online First: 24 April 2014].
29. Gianniou C, Dirani A, Ferrini W, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. *Eye (Lond)* 2015;29:342-9 doi: 10.1038/eye.2014.258 [published Online First: 02 November 2014].
30. Gillies MC, Nguyen V, Daien V, et al. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. *Ophthalmology* 2016;123:2545-53 doi: 10.1016/j.ophtha.2016.08.016 [published Online First: 07 October 2016].
31. Heimes B, Lommatzsch A, Zeimer M, et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. *Graefes Arch Clin Exp Ophthalmol* 2011;249:639-44 doi: 10.1007/s00417-010-1524-5 [published Online First: 05 October 2010].
32. Kang S, Roh YJ. Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration. *Jpn J Ophthalmol* 2011;55:123-7 doi: 10.1007/s10384-010-0910-1 [published Online First: 15 March 2011].
33. Lala C, Framme C, Wolf-Schnurrbusch UE, et al. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. *Acta Ophthalmol* 2013;91:526-30 doi: 10.1111/j.1755-3768.2012.02457.x [published Online First: 16 June 2012].
34. Liew G, Lee AY, Zarranz-Ventura J, et al. The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care. *Eye (Lond)* 2016;30:1462-68 doi: 10.1038/eye.2016.149 [published Online First: 16 July 2016].
35. Lotery A, Griner R, Ferreira A, et al. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. *Eye (Lond)* 2017;31:1697-706 doi: 10.1038/eye.2017.143 [published Online First: 22 July 2017].
36. Marques IP, Fonseca P, Luz Cachulo M, et al. Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up. *Ophthalmologica* 2013;229:158-67 doi: 10.1159/000343709 [published Online First: 15 March 2013].

37. Muftuoglu IK, Tsai FF, Gaber R, et al. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2017;255:709-17 doi: 10.1007/s00417-016-3547-z [published Online First: 24 November 2016].
38. Muniraju R, Ramu J, Sivaprasad S. Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration. *Ophthalmologica* 2013;230:27-33 doi: 10.1159/000350238 [published Online First: 03 May 2013].
39. Ozkaya A, Alkin Z, Togac M, et al. Five-year outcomes of ranibizumab in neovascular age-related macular degeneration: Real life clinical experience. *Korean J Ophthalmol* 2017;31:424-30 doi: 10.3341/kjo.2016.0125 [published Online First: 11 September 2017].
40. Parvin P, Zola M, Dirani A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept. *Graefes Arch Clin Exp Ophthalmol* 2017;255:2127-34 doi: 10.1007/s00417-017-3762-2 [published Online First: 12 August 2017].
41. Peden MC, Suner IJ, Hammer ME, et al. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. *Ophthalmology* 2015;122:803-8 doi: 10.1016/j.ophtha.2014.11.018 [published Online First: 19 January 2015].
42. Rasmussen A, Sander B, Larsen M, et al. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections. *Acta Ophthalmol* 2017;95:128-32 doi: 10.1111/aos.13233 [published Online First: 19 August 2016].
43. Rasmussen A, Bloch SB, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. *Ophthalmology* 2013;120:2630-6 doi: 10.1016/j.ophtha.2013.05.018 [published Online First: 09 July 2013].
44. Ricci F, Parravano M, Regine F, et al. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. *Eye (Lond)* 2016;30:1077-83 doi: 10.1038/eye.2016.95 [published Online First: 28 May 2016].
45. Saleh M, Kheliouen M, Tebeanu E, et al. Retreatment by series of three intravitreal injections of ranibizumab in neovascular age-related macular degeneration: long-term outcomes. *Graefes Arch Clin Exp Ophthalmol* 2013;251:1901-7 doi: 10.1007/s00417-013-2284-9 [published Online First: 23 Feburary 2013].
46. Westborg I, Granstam E, Rosso A, et al. Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. *Acta Ophthalmol* 2017;95:787-95 doi: 10.1111/aos.13539 [published Online First: 24 August 2017].
47. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. *Retina* 2008;28:1387-94 doi: 10.1097/IAE.0b013e3181884ff4 [published Online First: 12 October 2008].
48. Arevalo JF, Lasave AF, Wu L, et al. Intrvitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-Year results of The Pan-American Collaborative Retina Study Group. *Retina* 2016;36:859-67 doi: 10.1097/iae.0000000000000827 [published Online First: 04 November 2015].

49. Axer-Siegel R, Bor E, Bourla DH, et al. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. *Retina* 2012;32:1811-20 doi: 10.1097/IAE.0b013e31825db771 [published Online First: 25 July 2012].
50. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. *Am J Ophthalmol* 2009;148:59-65 e1 doi: 10.1016/j.ajo.2009.02.006 [published Online First: 21 April 2009].
51. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. *Am J Ophthalmol* 2008;145:249-56 doi: 10.1016/j.ajo.2007.09.031 [published Online First: 11 December 2007].
52. Bellerive C, Cinq-Mars B, Lalonde G, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. *Can J Ophthalmol* 2012;47:165-9 doi: 10.1016/j.jcjo.2012.01.011 [published Online First: 09 May 2012].
53. Beykin G, Grunin M, Averbukh E, et al. Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome. *BMC Ophthalmol* 2015;15:39 doi: 10.1186/s12886-015-0019-x [published Online First: 17 April 2015].
54. Calvo P, Abadia B, Ferreras A, et al. Long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections. *Journal of ophthalmology* 2015;2015:820605 doi: 10.1155/2015/820605 [published Online First: 23 October 2015].
55. Chang YS, Han JI, Yoo SJ, et al. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity. *Korean J Ophthalmol* 2014;28:466-72 doi: 10.3341/kjo.2014.28.6.466 [published Online First: 02 December 2014].
56. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. *Retina* 2013;33:474-81 doi: 10.1097/IAE.0b013e31827b6324.
57. De Bats F, Grange JD, Cornut PL, et al. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients. *J Fr Ophtalmol* 2012;35:661-6 doi: 10.1016/j.jfo.2012.01.015 [published Online First: 09 November 2012].
58. Eleftheriadou M, Gemenetzi M, Lukic M, et al. Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. *Ophthalmol Ther* 2018;7:361-68 doi: 10.1007/s40123-018-0139-5 [published Online First: 10 July 2018].
59. Gupta B, Adewoyin T, Patel SK, et al. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. *Br J Ophthalmol* 2011;95:386-90 doi: 10.1136/bjo.2010.179499 [published Online First: 10 August 2010].
60. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. *Journal of ophthalmology* 2011;2011:405724 doi: 10.1155/2011/405724 [published Online First: 17 December 2011].

61. Jacob J, Brie H, Leys A, et al. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. *Int J Ophthalmol* 2017;10:81-90 doi: 10.18240/ijo.2017.01.14 [published Online First: 06 February 2017].
62. Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. *Am J Ophthalmol* 2013;155:89-95.e3 doi: 10.1016/j.ajo.2012.06.031 [published Online First: 02 October 2012].
63. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. *Am J Ophthalmol* 2009;148:43-58.e1 doi: 10.1016/j.ajo.2009.01.024 [published Online First: 21 April 2009].
64. Mantel I, Niderprim SA, Gianniou C, et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. *Br J Ophthalmol* 2014;98:1192-6 doi: 10.1136/bjophthalmol-2013-304556 [published Online First: 15 April 2014].
65. Mekjavic PJ, Kraut A, Urbancic M, et al. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. *Acta Ophthalmol* 2011;89:647-53 doi: 10.1111/j.1755-3768.2009.01740.x [published Online First: 29 October 2009].
66. Messenger WB, Campbell JP, Faridi A, et al. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. *Br J Ophthalmol* 2014;98:1205-7 doi: 10.1136/bjophthalmol-2013-304829 [published Online First: 06 May 2014].
67. Muether PS, Hoerster R, Hermann MM, et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2013;251:453-8 doi: 10.1007/s00417-012-2038-0 [published Online First: 11 May 2012].
68. Ohnaka M, Nagai Y, Sho K, et al. A modified treat-and-extend regimen of aflibercept for treatment-naive patients with neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2017;255:657-64 doi: 10.1007/s00417-016-3507-7 [published Online First: 16 October 2016].
69. Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. *Clin Ophthalmol* 2013;7:1849-58 doi: 10.2147/opth.S49385 [published Online First: 05 October 2013].
70. van Asten F, Evers-Birkenkamp KU, van Lith-Verhoeven JJ, et al. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. *Acta Ophthalmol* 2015;93:126-33 doi: 10.1111/aos.12610 [published Online First: 10 December 2014].
71. Suzuki M, Gomi F, Sawa M, et al. Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. *Jpn J Ophthalmol* 2010;54:124-8 doi: 10.1007/s10384-009-0775-3 [published Online First: 20 April 2010].
72. Warwick AN, Leaver HH, Lotery AJ, et al. Fixed bimonthly aflibercept in naive and switched neovascular age-related macular degeneration patients: one year outcomes. *Int J Ophthalmol* 2016;9:1156-62 doi: 10.18240/ijo.2016.08.12 [published Online First: 03 September 2016].

73. Faure C, Cohen SY, Coscas F, et al. Real-world effectiveness and safety of intravitreal aflibercept regimens in patients with wet age-related macular degeneration: Updated 12-month outcomes of RAINBOW. *9th Congress on Controversies in Ophthalmology: Europe* 2018.
74. Lovestam Adrian M, Vassilev ZP, Westborg I. Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register. *Acta Ophthalmol* 2018 doi: 10.1111/aos.13864 [published Online First: 22 September 2018].
75. Barakat A, Rufin V, Tran THC. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept. *J Fr Ophtalmol* 2018;41:603-10 doi: 10.1016/j.jfo.2018.01.005 [published Online First: 01 September 2018].
76. Ono A, Shiragami C, Manabe S, et al. One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis. *Medicine (Baltimore)* 2018;97:e11737 doi: 10.1097/md.0000000000011737 [published Online First: 05 August 2018].
77. Chatziralli I, Regan SO, Mohamed R, et al. Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes. *Eye (Lond)* 2018;32:1523-29 doi: 10.1038/s41433-018-0114-3 [published Online First: 06 August 2018].
78. Brand C, Arnoldussen M. IRay therapy as an adjuvant therapy in newly diagnosed patients with neovascular age-related macular degeneration. *Eye (Lond)* 2018;32:1345-52 doi: 10.1038/s41433-018-0080-9 [published Online First: 18 April 2018].
79. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. *Retina* 2011;31:26-30 doi: 10.1097/IAE.0b013e3181de5609.
80. Hatz K, Prunte C. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. *Br J Ophthalmol* 2016;100:1341-5 doi: 10.1136/bjophthalmol-2015-307299 [published Online First: 11 January 2016].
81. Arnold JJ, Campain A, Barthelmes D, et al. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. *Ophthalmology* 2015;122:1212-9 doi: 10.1016/j.ophtha.2015.02.009 [published Online First: 04 April 2015].
82. Barthelmes D, Nguyen V, Daien V, et al. Two Year Outcomes of "Treat and Extend" Intravitreal Therapy Using Aflibercept Preferentially for Neovascular Age-Related Macular Degeneration. *Retina* 2018;38:20-28 doi: 10.1097/IAE.0000000000001496.
83. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. *Retina* 2014;34:1531-8 doi: 10.1097/iae.0000000000000134 [published Online First: 19 March 2014].
84. Castro-Navarro V, Cervera-Taulet E, Montero-Hernandez J, et al. Treat-and-extend approach with aflibercept: Effects on different subtypes of age-related choroidal neovascularisation. *Arch Soc Esp Oftalmol* 2017;92:112-19 doi: 10.1016/j.oftal.2016.09.005 [published Online First: 07 November 2016].

85. Castro-Navarro V, Cervera-Taulet E, Montero-Hernandez J, et al. One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation. *Ophthalmologica* 2016;236:215-22 doi: 10.1159/000453281 [published Online First: 12 December 2016].
86. Chen YN, Powell AM, Mao A, et al. Retrospective review of Lucentis "treat and extend" patterns and outcomes in age-related macular degeneration. *Retina* 2016;36:272-8 doi: 10.1097/iae.0000000000000691 [published Online First: 23 July 2015].
87. Garweg JG, Niderprim SA, Russ HM, et al. Comparison of strategies of treatment with ranibizumab in newly-diagnosed cases of neovascular age-related macular degeneration. *J Ocul Pharmacol Ther* 2017;33:773-78 doi: 10.1089/jop.2017.0006 [published Online First: 28 September 2017].
88. Giannakaki-Zimmermann H, Ebneter A, Munk MR, et al. Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. *Ophthalmologica* 2016;236:201-06 doi: 10.1159/000452929 [published Online First: 03 December 2016].
89. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. *Ophthalmology* 2010;117:2134-40 doi: 10.1016/j.ophtha.2010.02.032 [published Online First: 02 July 2010].
90. Hatz K, Prunte C. Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. *Acta Ophthalmol* 2017;95:e67-e72 doi: 10.1111/aos.13031 [published Online First: 25 March 2016].
91. Ito A, Matsumoto H, Morimoto M, et al. Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration. *Ophthalmologica* 2017;238:236-42 doi: 10.1159/000479937 [published Online First: 03 September 2017].
92. Mekjavic PJ, Zaletel Benda P. Outcome of 5-year treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF using "treat and extend" regimen. *Front Med (Lausanne)* 2018;5:125 doi: 10.3389/fmed.2018.00125 [published Online First: 17 May 2018].
93. Jorstad OK, Faber RT, Moe MC. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. *Acta Ophthalmol* 2017;95:460-63 doi: 10.1111/aos.13480 [published Online First: 31 May 2017].
94. Rahimy E, Rayess N, Ho AC, et al. Treatment outcomes for neovascular age-related macular degneration patients with initial vision better than 20/40 using a treat-and-extend regimen. *Retina* 2016;36:875-80 doi: 10.1097/iae.0000000000000814 [published Online First: 03 December 2015].
95. Rayess N, Houston SK, 3rd, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. *Am J Ophthalmol* 2015;159:3-8.e1 doi: 10.1016/j.ajo.2014.09.011 [published Online First: 15 Septermber 2014].
96. Vardarinos A, Gupta N, Janjua R, et al. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. *BMC Ophthalmol* 2017;17:58 doi: 10.1186/s12886-017-0451-1 [published Online First: 30 April 2017].

97. Yamamoto A, Okada AA, Nakayama M, et al. One-year outcomes of a treat-and-extend regimen of aflibercept for exudative age-related macular degeneration. *Ophthalmologica* 2017;237:139-44 doi: 10.1159/000458538 [published Online First: 06 March 2017].
98. Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. *Retina* 2010;30:1368-75 doi: 10.1097/IAE.0b013e3181d50cbf [published Online First: 03 June 2010].
99. Garweg JG, Gerhardt C, Kodjikian L, et al. Real-life experience with aflibercept and ranibizumab in the treatment of newly diagnosed neovascular age-related macular degeneration over 24 months. *J Ocul Pharmacol Ther* 2017;33:567-72 doi: 10.1089/jop.2017.0031 [published Online First: 31 May 2017].
100. Rush RB, Simunovic MP, Vandiver L, et al. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. *Retina* 2014;34:846-52 doi: 10.1097/iae.0000000000000033 [published Online First: 19 November 2013].
101. Sakamoto S, Takahashi H, Inoue Y, et al. Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study. *Clin Ophthalmol* 2018;12:1137-47 doi: 10.2147/opth.S160961 [published Online First: 05 July 2018].
102. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. *Am J Ophthalmol* 2012;153:468-73.e1 doi: 10.1016/j.ajo.2011.08.011 [published Online First: 15 October 2011].